Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2012
08/23/2012WO2012110636A2 Carrier peptides for cell delivery
08/23/2012WO2012110470A1 Novel benzodioxole piperazine compounds
08/23/2012WO2012110459A1 1,4-oxazepines as bace1 and/or bace2 inhibitors
08/23/2012WO2012110441A1 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
08/23/2012WO2012110440A1 6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one derivatives their use as pde9a inhibitors
08/23/2012WO2012110190A1 Novel p2x7r antagonists and their use
08/23/2012WO2012110017A1 Dietetic or pharmaceutical preparation containing tartary buckwheat
08/23/2012WO2012110010A1 Pregnanolone derivatives substituted in 3alpha-position with the cationic group, method of their production, usage and pharmaceutical preparation involving them
08/23/2012WO2012109976A1 Use of α-mangostin in preparation of medicaments for treating alzheimer's disease
08/23/2012WO2012109695A1 Drug compositions for the treatment of insomnia
08/23/2012WO2012080727A3 Casein kinase 1delta (ck1delta) inhibitors
08/23/2012WO2012074440A3 Pharmacological composition intended for intra-nasal administration with the aim of supplying a pharmacologically active component to the brain, and method for producing said composition
08/23/2012WO2012025213A3 Novel therapeutic compounds
08/23/2012WO2012020423A8 Role of an herbal formulation in the prevention and management of age related neurodegenerative disorders with special reference to senile dementia
08/23/2012US20120216302 Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
08/23/2012US20120214877 Stable rasagiline composition
08/23/2012US20120214876 Seizure and Migraine Treatments using the Bone Homeostasis Drug Cinacalcet
08/23/2012US20120214869 Novel ligand activators of the rar receptors and pharmaceutical/cosmetic applications thereof
08/23/2012US20120214866 Treatment with cytokines
08/23/2012US20120214865 Methods for slowing familial als disease progression
08/23/2012US20120214861 Methods and compositions for treating neurological disease
08/23/2012US20120214860 Method of regulating the expression level of survival of motor neuron 1 (smn1) and detecting enzyme activity of ubiquitin carboxyl-terminal hydrolase l1 (uchl1)
08/23/2012US20120214859 Methods and compositions for improving cognitive function
08/23/2012US20120214858 Imidamide sphingosine kinase inhibitors
08/23/2012US20120214847 2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS
08/23/2012US20120214846 Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
08/23/2012US20120214845 Active metabolite of a thrombin receptor antagonist
08/23/2012US20120214841 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
08/23/2012US20120214839 Treatment of progressive neurodegenerative disease with ibudilast
08/23/2012US20120214838 THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS
08/23/2012US20120214837 Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
08/23/2012US20120214827 Anhydrous Crystalline Forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
08/23/2012US20120214824 Proteostasis regulators
08/23/2012US20120214820 Orally disintegrating pharmaceutical dosage form containing aripiprazole
08/23/2012US20120214817 Urotensin ii receptor antagonists
08/23/2012US20120214815 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses
08/23/2012US20120214814 Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at c-17
08/23/2012US20120214812 Compounds and compositions as lxr modulators
08/23/2012US20120214808 Aryl Urea Derivatives for Treating Obesity
08/23/2012US20120214807 Compounds useful as antagonists of ccr2
08/23/2012US20120214806 3-amino-5-phenyl-5,6-dihydro-2h-[1,4]oxazines
08/23/2012US20120214804 Pharmaceutical composition comprising indole compound
08/23/2012US20120214802 Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
08/23/2012US20120214799 Kinase inhibitors
08/23/2012US20120214793 Sleep aid composition and method
08/23/2012US20120214791 Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders
08/23/2012US20120214790 N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof
08/23/2012US20120214784 Spiropiperidine compounds as orl-1 receptor antagonists
08/23/2012US20120214779 Application of 20(s)-protopanaxadiol in preparation of antidepressants
08/23/2012US20120214771 Compositions for treatment of cardiometabolic disorders
08/23/2012US20120214763 Memory fixation accelerator
08/23/2012US20120214762 6,5-heterocyclic propargylic alcohol compounds and uses therefor
08/23/2012US20120214754 Fgf receptor-activating n-acyl octasaccharides, preparation thereof, and therapeutic use thereof
08/23/2012US20120214742 Gaba release-regulating agent in cerebellum
08/23/2012US20120214737 Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by nrg-2
08/23/2012US20120214733 Oxytocin receptor agonists
08/23/2012US20120214731 Compound ws 727713
08/23/2012US20120214729 Composition for preventing or treating inflammation
08/23/2012US20120213872 Compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof
08/23/2012US20120213863 Therapeutic gas for the treatment of mitochondrial disorders
08/23/2012US20120213860 Xenon-based inhalable drug for treating or preventing induced dyskinesia
08/23/2012US20120213850 Controlled Release and Taste Masking Oral Pharmaceutical Composition
08/23/2012US20120213833 Prevotella histicola preparations and the treatment of autoimmune conditions
08/23/2012US20120213829 Dry powder aerosols of nanoparticulate drugs
08/23/2012US20120213823 Compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof
08/23/2012US20120213807 Neprilysin inhibitors
08/23/2012US20120213806 Neprilysin inhibitors
08/23/2012US20120213803 Methods for diagnosing and treating encephalitis or epilepsy
08/23/2012US20120213799 Compositions and methods for treating inflammatory disorders
08/23/2012US20120213791 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
08/23/2012US20120213790 Methods of treatment using il-16 antagonist peptides
08/23/2012US20120213785 Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
08/23/2012US20120213784 Method for the potentiation of opioid analgesics effects on pain
08/23/2012US20120213778 Method of detecting and treating tuberous sclerosis complex associated disorders
08/23/2012US20120213776 Antibodies to granulocyte-macrophage colony-stimulating factor
08/23/2012US20120213773 Binding domain-immunoglobulin fusion proteins
08/23/2012US20120213769 Methods of diagnosing amyotrophic lateral sclerosis (als)
08/23/2012US20120213767 Extended Soluble PH20 Polypeptides and uses thereof
08/23/2012US20120213757 Nutritional supplement composition
08/23/2012US20120213731 Methods and compositions for treating autoimmune diseases
08/23/2012US20120213727 Therapeutic uses of oligomeric and polymeric monoterpenes
08/23/2012CA2827724A1 Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
08/23/2012CA2827383A1 Molecular switch for neuronal outgrowth
08/23/2012CA2827288A1 Methods and compositions of producing patient-specific multipotent neuronal stem cells
08/23/2012CA2827261A1 6-cyclobutyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
08/23/2012CA2823988A1 Novel benzodioxole piperazine compounds
08/23/2012CA2823877A1 Novel pyrazole and imidazole derivatives useful as orexin antagonists
08/23/2012CA2822534A1 1,4-oxazepines as bace1 and/or bace2 inhibitors
08/23/2012CA2732440A1 Cystamine analogues for the treatment of parkinson`s disease
08/22/2012EP2489675A1 ANTIBODY RECOGNIZING TURN STRUCTURE IN AMYLOID ß
08/22/2012EP2489667A1 Quinoxaline derivative
08/22/2012EP2489663A1 Compounds as syk kinase inhibitors
08/22/2012EP2489371A1 Carrier peptides for drug delivery
08/22/2012EP2489361A1 Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
08/22/2012EP2489353A1 Sofinicline (ABT-894) for attention-deficit/hyperactivity disorder
08/22/2012EP2488643A1 Chimeric fibroblast growth factors with altered receptor specificity
08/22/2012EP2488550A2 Mutant low-density lipoprotein receptor related protein with increased binding to alzheimer amyloid-beta peptide
08/22/2012EP2488530A1 Spirocyclic piperidine derivatives useful as renin inhibitors
08/22/2012EP2488528A1 Pyrrolo [3,2 -e][1,2,4]triazolo [1,5-a]pyrimidines derivatives as inhibitors of microglia activation
08/22/2012EP2488527A1 Pyrrolo [3, 2 -e][1,2,4]triazolo [1,5 -a]pyrimidines derivatives as inhibitors of microglia activation
1 ... 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 ... 1833